33553 Real-world treatment patterns and outcomes up to 1 year among children aged <12 years with moderate-to-severe atopic dermatitis (AD) enrolled in the PEDIatric STudy in Atopic Dermatitis (PEDISTAD) observational study

医学 特应性皮炎 湿疹面积及严重程度指数 杜皮鲁玛 皮肤科生活质量指数 甲氨蝶呤 生活质量(医疗保健) 体表面积 儿科 皮肤病科 斯科拉德 内科学 银屑病 护理部
作者
Eulàlia Baselga,Nikolay N. Murashkin,Myong Soon Sung,Lara Wine Lee,Chunyuan Liu,Lauren Bates,Annie Zhang
出处
期刊:Journal of The American Academy of Dermatology [Elsevier BV]
卷期号:87 (3): AB200-AB200
标识
DOI:10.1016/j.jaad.2022.06.831
摘要

Background: We describe real-world treatment patterns in patients aged <12 years with moderate-to-severe AD, focusing on systemic treatments. Methods: PEDISTAD (NCT03687359) is an ongoing, international, noninterventional registry in patients aged <12 years with moderate-to-severe AD inadequately controlled with topical therapies. Treatment was per investigator discretion. In this interim analysis (data cutoff 30 July 2020), we report baseline data for all patients, and changes in the following outcomes (from therapy start [TS] to last observation [LO]) for patients receiving systemic treatments of interest (dupilumab, cyclosporine, or methotrexate): Eczema Area and Severity Index (EASI), AD-affected body surface area (BSA), Patient-Oriented Eczema Measure (POEM), Children’s Dermatology Life Quality Index (CDLQI; 4–<12 years), and current-day peak pruritus numerical rating scale (PP-NRS). No formal statistical testing was performed. Results: At baseline, 77.2% (565/732) of patients were receiving nonsystemic AD therapies (topical corticosteroids: 69.9%); 23.1% were receiving systemic therapies, including: dupilumab: 2.6% [n = 19]; cyclosporine: 8.1% [n = 59]; and methotrexate: 9.0% [n = 66]. The median duration of patient follow-up was 8.7 months. Physician-reported outcomes (change in mean ± SD) improved from TS to LO: EASI (dupilumab [n = 31], cyclosporine [n = 80], methotrexate [n = 69]: -13.8 ± 15.4, -4.6 ± 12.2, -6.2 ± 12.8) and % BSA (-18.4 ± 25.0, -13.6 ± 22.3, -14.6 ± 18.8). Change in patient/caregiver-reported outcomes were: POEM (-7.6 ± 8.5, -2.1 ± 11.1, -4.3 ± 11.2), CDLQI (-7.2 ± 7.8, 0.3 ± 5.5, -2.9 ± 6.8) and PP-NRS (-2.6 ± 2.3, 0.7 ± 3.0, 0.6 ± 2.5). Time-to-discontinuation (mean ± SD, months) was: dupilumab (8.6 ± 6.4); cyclosporine (5.2 ± 4.1); methotrexate (7.0 ± 4.7). Conclusions: The most common treatment at baseline for children aged <12 years with moderate-to-severe AD was topical corticosteroids. Dupilumab was associated with greater improvements in clinical assessments/patient-reported outcomes vs other systemic therapies.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
庾幻儿完成签到,获得积分10
刚刚
刚刚
小玉完成签到,获得积分20
1秒前
认真的TOTORO完成签到,获得积分10
1秒前
alala完成签到,获得积分10
1秒前
乐开欣完成签到,获得积分10
1秒前
JC325T发布了新的文献求助10
1秒前
驿路梨花发布了新的文献求助30
1秒前
兰兰发布了新的文献求助10
1秒前
Peggy完成签到,获得积分10
1秒前
我是科研狗完成签到 ,获得积分10
1秒前
我有一头小毛驴完成签到,获得积分10
1秒前
1秒前
cell发布了新的文献求助10
1秒前
Rondab应助左彦采纳,获得50
1秒前
2秒前
2秒前
byyyy发布了新的文献求助10
2秒前
2秒前
夏沐完成签到,获得积分20
3秒前
细腻海蓝发布了新的文献求助10
3秒前
4秒前
舒适香露发布了新的文献求助10
4秒前
直率青亦发布了新的文献求助10
4秒前
Jasper应助懒羊羊采纳,获得10
4秒前
宫跃然发布了新的文献求助10
5秒前
李大宝发布了新的文献求助10
5秒前
5秒前
5秒前
繁荣的忆文完成签到,获得积分10
6秒前
qaz123发布了新的文献求助10
6秒前
6秒前
7秒前
7秒前
小怪完成签到,获得积分10
8秒前
FashionBoy应助小甑采纳,获得10
8秒前
在水一方应助周游采纳,获得10
8秒前
爆米花应助科研一号采纳,获得10
9秒前
9秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969322
求助须知:如何正确求助?哪些是违规求助? 3514152
关于积分的说明 11172188
捐赠科研通 3249407
什么是DOI,文献DOI怎么找? 1794832
邀请新用户注册赠送积分活动 875437
科研通“疑难数据库(出版商)”最低求助积分说明 804781